{"id":"investigational-mrna-1273-815","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain/erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL5315014","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This investigational vaccine uses lipid nanoparticle-formulated mRNA to instruct cells to produce antigen proteins that trigger both humoral and cellular immune responses. The .815 designation indicates a variant-updated formulation targeting emerging SARS-CoV-2 strains beyond the original Wuhan strain. The vaccine aims to provide broader or enhanced protection against circulating variants of concern.","oneSentence":"mRNA-1273.815 is an mRNA vaccine encoding modified spike proteins designed to elicit immune responses against SARS-CoV-2 variants.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:53.030Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention (variant-updated formulation)"}]},"trialDetails":[{"nctId":"NCT06354998","phase":"PHASE3","title":"A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-04-08","conditions":"SARS-CoV-2","enrollment":217}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Investigational mRNA-1273.815","genericName":"Investigational mRNA-1273.815","companyName":"ModernaTX, Inc.","companyId":"modernatx-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"mRNA-1273.815 is an mRNA vaccine encoding modified spike proteins designed to elicit immune responses against SARS-CoV-2 variants. Used for COVID-19 prevention (variant-updated formulation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}